Revenue Breakdown
Composition ()
No data
Revenue Streams
Insight Molecular Diagnostics Inc (IMDX) generates its revenue primarily from Pharma Services, which accounts for 100.0% of total sales, equivalent to $260.00K. Understanding this concentration is critical for investors evaluating how IMDX navigates market cycles within the Biotechnology & Medical Research industry.
Profitability & Margins
Evaluating the bottom line, Insight Molecular Diagnostics Inc maintains a gross margin of 43.55%. This metric reflects the company's pricing power and manufacturing efficiency. Further down the income statement, the operating margin stands at -873.57%, while the net margin is -2015.36%. These profitability ratios, combined with a Return on Equity (ROE) of N/A, provide a clear picture of how effectively IMDX converts its operational activities into shareholder value.
Comparative Benchmarking
In the context of the broader market, IMDX competes directly with industry leaders such as KLRS and BDTX. With a market capitalization of $120.95M, it holds a significant position in the sector. When comparing efficiency, IMDX's gross margin of 43.55% stands against KLRS's N/A and BDTX's 100.00%. Such benchmarking helps identify whether Insight Molecular Diagnostics Inc is trading at a premium or discount relative to its financial performance.
